International Society for Pharmaceutical Engineering members developed the guide to offer a risk-based framework for evaluating, implementing, and maintaining AI systems.
- In Vivo's Biggest Threat — Comparison To Old Models
- Managing Supply Chain Risk In Scale-Up And Multisite Trials
- The 5-Layer Fix For AI Failure In Pharmaceutical Manufacturing
- Why Use Total Organic Carbon Analysis For Cleaning Validation?
- December 2025 — CDMO Opportunities And Threats Report
- Do's And Don'ts Of Material Handling When Retrofitting For ADCs
- Building Enterprise Resilience From QRM Signals
EDITOR'S DESK
-
FDA Releases Draft Guidance To Accelerate Biosimilar Development
New FDA draft guidance aims to reduce the timeline and cost of developing biosimilars.
Experts discuss innovation in antibody-drug conjugate (ADC) technology and how these impact CMC strategy. This summary captures key takeaways from the Bioprocess Online Live event "Evolving CMC Strategies To Enable Next-Gen ADCs."
Capacity isn’t the choke point—capability is; this piece ranks nine fast-growing outsourcing segments and shows sponsors how to win by locking in modality-proven partners early.
At BioProcess International 2025, leaders from AbbVie and Amgen gave keynote presentations about how their companies are advancing product development through digital tools.
AI consultant Kat Kozyrytska advocates for ethical AI adoption and explains its potential to foster collaboration across the industry.
GUEST COLUMNISTS
-
Managing Supply Chain Risk In Scale-Up And Multisite Trials
Scaling trials across sites can lock in supply risk early. Learn how biologic variability, long lead times, and multisite complexity threaten trials and how to spot warning signs fast.
-
The 5-Layer Fix For AI Failure In Pharmaceutical Manufacturing
The promise of AI is colliding with the harsh reality of data chaos in pharma manufacturing. This article explores why most AI investments fail, and a 5-layer solution.
-
Why Use Total Organic Carbon Analysis For Cleaning Validation?
Total organic carbon analysis is probably the most “fit for use” analytical method to validate cleaning processes, particularly within a science- and risk-based approach.
-
December 2025 — CDMO Opportunities And Threats Report
Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
-
Do's And Don'ts Of Material Handling When Retrofitting For ADCs
Antibody-drug conjugate manufacturing includes extremely dangerous ingredients, and most legacy facilities lack the features and flows for safe handling.
-
Building Enterprise Resilience From QRM Signals
Turn enterprise resource management (ERM) from a checklist into a true decision system — so risk informs everyday choices before quality events become supply disruptions, delays, or regulatory exposure.
-
Single-Use Standards Are Maturing, But The Process Remains King
The food industry inspired single-use in biopharma, but the regulatory landscape is far more complex. If you're worried about compliance, this discussion can help.
-
Mind The Potent Compounds When Retrofitting Facilities For ADCs
Antibody-drug conjugate manufacturing introduces significantly more risk to employees. Likewise, facility safety requirements are especially intense.
BIOPROCESSING WHITE PAPERS
-
A Toolbox For An Effective Tech Transfer
As drug development costs rise, companies are embracing digital-first strategies and Pharma 4.0 principles to streamline operations, enhance tech transfer, and accelerate time-to-market through innovation.
-
Unlocking ROI And Capacity In Monoclonal Antibody Manufacturing11/5/2025
Perfusion-based upstream production offers up to 24% lower cost and significantly higher productivity than fed-batch, enabling faster timelines, better facility utilization, and improved quality.
-
If You Can't Win The Game, Change It12/11/2024
Explore how eData sharing is used in the biopharma market, enabling standardized, collaborative supply chains that reduce risks and enhance visibility while improving capacity planning.
-
Application Of Plant And Process Models1/22/2025
Explore innovative process and facility models that optimize efficiency, sustainability, and cost-effectiveness in biopharmaceutical manufacturing.
-
Physiologix Serum Replacement Performance On T Cells9/16/2024
A serum replacement for promoting T cell growth and functionality in cell therapy development shows comparable or superior performance to traditional human serum supplements.
-
The Advantages Of A Blended Learning Approach In Operator Training5/30/2024
Explore blended learning and its advantages over traditional operator training methods, which often reduce training to a repetitive but necessary checklist of reading and acknowledging procedures.
BIOPROCESSING APP NOTES & CASE STUDIES
- Improved T Cell Expansion Using Closed, Automated Stirred-Tank Bioreactors
- Rheological Properties Of Pharmaceutical Excipients: Lactose Monohydrate And Carboxymethyl Cellulose
- PPQ: Early Adoption Of Digital Process Systems Puts You In Control
- Simplified LV And AAV Clarification With TFDF-Based Intensified Virus Production
- A Non-Viral Workflow For Modifying Primary T Cells
- Taking The First Steps Towards Digitalizing Biopharma Development
- Bioprocess Online's 2025 Editorial Reflections
- FDA Releases Draft Guidance To Accelerate Biosimilar Development
- Supporting The Next Generation Of ADCs
- AbbVie And Amgen's Blueprint To Digitalize Biomanufacturing
- On The Ground At BPI: Kat Kozyrytska On Ethical AI And Collaboration
- On The Ground At BPI: Takeda's Amy Shaw On Scaling Cell Therapy Manufacturing
BIOPROCESS ONLINE CONTENT COLLECTIONS
This collection of articles digs into the industry’s growing focus on knowledge management as an indispensable facet of biomanufacturing and pharmaceutical development, exploring how it plays into risk management, quality, vendor relationships, and supply chain resilience.
More Content CollectionsFEATURED PRODUCTS AND SERVICES
ON-DEMAND WEBINARS
- Simplified Harvest And Media Exchange In Cell Therapy
- Next-Level Cell Lines: An Integrated Approach To Biologic Innovation
- Turbocharging pDNA Production: CDMO Case Study In Optimization
- Beyond Geographies — Derisking Global Manufacturing
- Sterile Filling Readiness In The Drug Device Delivery Ecosystem
INDUSTRY NEWS
NEWSLETTER ARCHIVE
- 01.29.26 -- Mind The Potent Compounds When Retrofitting Facilities For ADCs
- 01.28.26 -- Why Use Total Organic Carbon Analysis For Cleaning Validation?
- 01.27.26 -- A Deeper Look At Pharma's Structural Supply Chain Vulnerability
- 01.26.26 -- A Multi-Omics Approach For Characterizing Clinical-Scale iPSC Batches
- 01.23.26 -- STREAM Edition: How To Strategically Integrate New Technology Into Existing Workflows